SalMar ASA (SALRF)
OTCMKTS
· Delayed Price · Currency is USD
51.06
0.00 (0.00%)
At close: Oct 29, 2024
SalMar ASA Revenue
SalMar ASA had revenue of 6.10B NOK in the quarter ending September 30, 2024, a decrease of -18.03%. This brings the company's revenue in the last twelve months to 26.21B, down -0.55% year-over-year. In the year 2023, SalMar ASA had annual revenue of 27.89B with 39.56% growth.
Revenue (ttm)
26.21B NOK
Revenue Growth
-0.55%
P/S Ratio
n/a
Revenue / Employee
10.57M NOK
Employees
2,479
Market Cap
6.28B USD
Revenue Chart
* This company reports financials in NOK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 27.89B | 7.91B | 39.56% |
Dec 31, 2022 | 19.98B | 5.02B | 33.56% |
Dec 31, 2021 | 14.96B | 2.07B | 16.01% |
Dec 31, 2020 | 12.90B | 668.50M | 5.47% |
Dec 31, 2019 | 12.23B | 907.65M | 8.02% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSalMar ASA News
- 6 days ago - SalMar - 2024 share-based incentive scheme for senior executives and key personnel - GlobeNewsWire
- 5 weeks ago - SalMar - Sale by primary insiders in connection with release of employee restricted share units completed - GlobeNewsWire
- 5 weeks ago - Q3 2024 SalMar ASA Earnings Call(recording) Transcript - GuruFocus
- 5 weeks ago - SalMar - Release of employee restricted share units - GlobeNewsWire
- 5 weeks ago - SalMar ASA (SALRF) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - SalMar ASA 2024 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 5 weeks ago - SalMar Non-GAAP EPS of NOK 2.80; lowers FY24 volume guidance and initiates FY25 outlook - Seeking Alpha
- 5 weeks ago - SalMar - Satisfactory financial results despite a period marked by biological challenges - GlobeNewsWire